Answers are grounded in this paper and cite their sources.
Many top-selling Medicare drugs received low added benefit ratings by the national HTA organizations of Canada, France, and Germany. When negotiating prices for these drugs, Medicare should ensure they are not priced higher than reasonable therapeutic alternatives.
No takes yet. Share an insight, caveat, or question.
Egilman et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: